参考文献:1.Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMed CrossRef 2.Jansen EP, Boot H, Verheij M et al (2005) Optimal locoregional treatment in gastric cancer. J Clin Oncol 23:4509–4517PubMed CrossRef 3.Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMed CrossRef 4.Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321PubMed CrossRef 5.Kinoshita T, Sasako M, Sano T et al (2009) Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 12:37–42PubMed CrossRef 6.Yoshikawa T, Sasako M, Yamamoto S et al (2009) Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 96:1015–1022PubMed CrossRef 7.Inoue T, Yachida S, Usuki H et al (2012) Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. Ann Surg Oncol 19:2937–2945PubMed CrossRef 8.Yoshikawa T, Tsuburaya A, Sano T et al (2011) Gastric cancer Surgical Study Group of Japan Clinical Oncology Group A phase II study of preoperative chemotherapy with S-1 (S) and cisplatin (P) followed by D3 gastrectomy for gastric cancer (GC) with extensive lymph node metastasis (ELM): survival results of JCOG0405. J Clin Oncol 29:2011(Suppl. 4) 9.Tsuburaya A, Mizusawa J, Tanaka Y et al (2014) Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101:653–660PubMed CrossRef 10.Kawaguchi T, Ichikawa D, Komatsu S et al (2011) Clinical evaluation of JCGC and TNM staging on multidetector-row computed tomography in preoperative nodal staging of gastric cancer. Hepatogastroenterology 58:838–841PubMed 11.Kawaguchi T, Komatsu S, Ichikawa D et al (2012) Nodal counts on MDCT as a surrogate marker for surgical curability in gastric cancer. Ann Surg Oncol 19:2465–2470PubMed CrossRef 12.Tokunaga M, Sugisawa N, Tanizawa Y et al (2013) The impact of preoperative lymph node size on long-term outcome following curative gastrectomy for gastric cancer. Ann Surg Oncol 20:1598–1603PubMed CrossRef 13.Kwee RM (2009) Kwee TC Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 12:6–22PubMed CrossRef 14.Shinohara T, Ohyama S, Yamaguchi T et al (2005) Clinical value of multidetector row computed tomography in detecting lymph node metastasis of early gastric cancer. Eur J Surg Oncol 31:743–748PubMed CrossRef 15.Hasegawa S, Yoshikawa T, Shirai J et al (2013) A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol 20:2016–2022PubMed CrossRef 16.Morgagni P, Petrella E, Basile B et al (2012) Preoperative multidetector-row computed tomography scan staging for lymphatic gastric cancer spread. World J Surg Oncol 10:197PubMed PubMedCentral CrossRef 17.Fukuya T, Honda H, Hayashi T et al (1995) Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 197:705–711PubMed CrossRef 18.Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma 3rd English edition. Gastric Cancer 14:101–112CrossRef 19.Makino M, Moriwaki S, Yonekawa M et al (1991) Prognostic significance of the number of metastatic lymph nodes in patients with gastric cancer. J Surg Oncol 47:12–16PubMed CrossRef 20.Jaehne J, Meyer HJ, Maschek H et al (1992) Lymphadenectomy in gastric carcinoma. A prospective and prognostic study. Arch Surg 127:290–294PubMed CrossRef 21.Ichikura T, Tomimatsu S, Okusa Y et al (1993) Comparison of the prognostic significance between the number of metastatic lymph nodes and nodal stage based on their location in patients with gastric cancer. J Clin Oncol 11:1894–1900PubMed 22.Roder JD, Bottcher K, Siewert JR et al (1993) Prognostic factors in gastric carcinoma. results of the German gastric carcinoma study 1992. Cancer 72:2089–2097PubMed CrossRef 23.Adachi Y, Kamakura T, Mori M et al (1994) Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br J Surg 81:414–416PubMed CrossRef 24.Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMed CrossRef 25.Knight G, Earle CC, Cosby R et al (2013) Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer 16:28–40PubMed CrossRef 26.Iwasaki Y, Sasako M, Yamamoto S et al (2013) Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol 107:741–745PubMed CrossRef
1. Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 6028566, Japan
刊物类别:Medicine
刊物主题:Medicine & Public Health Surgery Abdominal Surgery Cardiac Surgery General Surgery Thoracic Surgery Vascular Surgery
出版者:Springer New York
ISSN:1432-2323
文摘
Background This study was designed to establish a new diagnostic criteria of preoperative nodal status with high specificity on multidetector row computed tomography (MDCT) to extract advanced gastric cancer (GC) patients with an unfavorable prognosis.